Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Basic toxicokinetics

Currently viewing:

Administrative data

basic toxicokinetics in vivo
Type of information:
experimental study
Adequacy of study:
supporting study
Study period:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: human study

Data source

Reference Type:
study report
Report date:

Materials and methods

Objective of study:
Test guideline
no guideline available
Principles of method if other than guideline:
Healthy human subjects are exposed to two UV filters (Ethylhexyl Methoxycinnamate and Butyl Methoxydibenzoylmethane), investigating the absorption and excretion of the substances.
GLP compliance:

Test material

Constituent 1
Chemical structure
Reference substance name:
2-ethylhexyl 4-methoxycinnamate
EC Number:
EC Name:
2-ethylhexyl 4-methoxycinnamate
Cas Number:
Molecular formula:
2-​Propenoic acid, 3-​(4-​methoxyphenyl)​-​, 2-​ethylhexyl ester, (2E)​-
Details on test material:
- Name of test material (as cited in study report): Ethylhexyl methoxycinnamate, Butyl Methoxydibenzoylmethane
- Physical state: Liquid
- Specific activity (if radiolabelling): 125 uCi/ml (14C)
Specific details on test material used for the study:
4 % w/v of unlabelled material in solution

Test animals


Administration / exposure

Route of administration:
other: carbitol
Duration and frequency of treatment / exposure:
8 hours single treatment
Doses / concentrations
Dose / conc.:
25 other: μCi
Doses / Concentrations: 4 %
No. of animals per sex per dose / concentration:
4 subjects, of which 1 for pilot study
Control animals:

Results and discussion

Preliminary studies:
Recovery Ethylhexyl Methoxycinnamate from subject 1:
Skin (by stripping): 0.18 µCi = 0.72 %
Plasma: not detectable
Urine: 0.170 µCi = 0.16 %
Faeces: not detectable

Toxicokinetic / pharmacokinetic studies

Details on absorption:
Skin (stripping):
Subject 2: 1 %
Subject 3: 0.28 %
Subject 4: 0.48 %
Details on distribution in tissues:
Plasma: not detectable
Details on excretion:
Subject 2: 0.16 %
Subject 3: 0.2 %
Subject 4: 0.12 %

Subject 2: not detectable
Subject 3: not detectable
Subject 4: not detectable

Metabolite characterisation studies

Metabolites identified:
not measured
Details on metabolites:
Not relevant

Any other information on results incl. tables

Total recovery for both the pilot and main study:

- Subject 1 (pilot): 92.3 %

- Subject 2: 90.6 %

- Subject 3: 98.2 %

- Subject 4: 93.0 %

According to OECD 427, 100 ± 10 % of test substance should be recovered in an in vivo (animal) study, this human study fulfills that requirement.

In the preliminary study an occlusive application method was used. In the main study occlusion was not used.

Occlusion (pilot study) did not appear to increase the absorption of tracer from the combined substances.

There were no clinically significant adverse reactions.

Recovery of labeled Ethylhexyl Methoxycinnamate (with unlabeled Butyl Methoxydibenzoylmethane 1789) from urine was significantly higher than that of labeled Butyl Methoxydibenzoylmethane 1789 (with unlabeled Ethylhexyl Methoxycinnamate 1789), but still extremely low.

Applicant's summary and conclusion

Ethylhexyl Methoxycinnamate (containing Butyl Methoxydibenzoylmethane) shows a very low percutaneous absorption, that is indicated by very high recovery of the dose from the skin, undetectable radioactivity in plasma and faeces and a very low percentage of applied dose excreted in the urine. Therefore, it can be concluded that Ethylhexyl Methoxycinnamate does not bioaccumulate in human under the study conditions.
Executive summary:

1 healthy subject was treated with Ethylhexyl Methoxycinnamate (containing unlabelled Butyl Methoxydibenzoylmethane) for 8 hours in a preliminary study (for determination of activity to be applied), 3 healthy subjects were used in the main study. The preliminary study used occlusive application, in the main study no occlusion was applied. Subjects were screened (physical examination) and tested for derivations of haematology, serum chemistry and urinanalysis. Radioactivity (= amount of UV-Filter) was determined in skin (upper layer), plasma, urine and faeces.

No adverse effects were found after treatment in any of the subjects. Occlusion did not seem to have effect on the percutaneous absorption. In skin and urine only a very low amount of the radioactivity was recovered (maximum 1 %). In plasma and faeces no radioactivity was detectable. Therefore it is concluded that Ethylhexyl Methoxycinnamate shows only slight absorption into skin, and does not bioaccumulate.